Results 211 to 220 of about 197,173 (246)

Low-dose TNF-α drives malignant progression and lipid metabolism in glioblastoma through the TRAF2-FASN axis. [PDF]

Cell Death Discov
Cai M, Liu Y, Mao X, Wu Y, Sun S, Zhou J, Huang T, Jiao J.   +7 more
europepmc   +1 more source

Current Status and Evolution of Immunotherapy in Glioma Management. [PDF]

Int J Med Sci
Liu J, Yang G, Cao Z, Qin H, Zhu M, Zou C, Liu X, He Y, Gu J.   +8 more
europepmc   +1 more source

An Exceptional Case of Crohn-Associated IgA-Mediated Goodpasture Disease. [PDF]

Kidney Med
Ryan R, Fairhead T, Seager S, Jain M, Clark R.   +4 more
europepmc   +1 more source

Anti-glomerular basement membrane disease-treatment standard. [PDF]

Nephrol Dial Transplant
McAdoo SP, Pusey CD.
europepmc   +1 more source

Anti-GBM Antibodies in Crescentic Nephritis Without Kidney Binding

, 2017
Sadeghi-Alavijeh, O, Henderson, S, Bass, P, de Groot, K, Salama, AD   +4 more
openaire   +1 more source

Natural anti-GBM antibodies from normal human sera recognize α3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease

Clinical Immunology, 2007
Anti-GBM disease is a rare autoimmune condition characterized by autoantibodies targeting the alpha3 chain non-collagen 1 domain of type IV collagen (alpha3(IV)NC1). Recently, we isolated IgG reacting with alpha3(IV)NC1 from normal healthy human sera.
Rui Yang, Zhao Cui, Thomas Hellmark
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Relationship between anti-GBM antibodies and kidney outcomes in patients with anti-GBM disease

Journal of Nephrology, 2022
Abstract Introduction Animal experiments have shown that anti-GBM antibodies play a pathogenic role in anti-GBM disease. However, the relationship between anti-GBM antibody levels and kidney outcomes in patients with anti-GBM disease is unclear.
Ying Jin
exaly   +3 more sources